Eton Pharmaceuticals Gains U.S. Rights to IMPAVIDO with September 2026 Launch
Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO (miltefosine), the only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis. The supply and distribution deal with Knight’s affiliate expands Eton’s orphan drug portfolio and positions the company to serve patients aged 12 and older across specialized leishmaniasis indications.
1. Agreement Terms and Effective Date
In May 2026, Eton signed a supply and distribution agreement with a Knight affiliate granting exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine), with rights taking effect on September 26, 2026.
2. IMPAVIDO Profile and Indications
IMPAVIDO is the only FDA-approved oral treatment for visceral, cutaneous, and mucosal leishmaniasis in patients aged 12 and older weighing at least 30 kg, addressing a rare parasitic disease that can cause severe skin lesions or systemic infection.
3. Strategic Fit and Portfolio Expansion
This transaction adds another orphan therapy to Eton’s 2026 pipeline, enhancing the company’s ability to deliver high-touch access and support for specialized patient populations across multiple leishmaniasis indications.